Clinical Trial Update: Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating an in vivo CD19-targeted CAR-T/M therapy delivered by an oncolytic vaccinia virus for refractory/relapsed B-cell lymphoma, c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Oncolytic vaccinia virus delivering targeted CD19 in vivo CAR-T/M therapy

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Refractory/Relapsed B-cell Lymphoma | Phase 1 | Status: RECRUITING